CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of Olorinab in Subjects With Irritable Bowel Syndrome Experiencing Abdominal Pain

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04043455
Title field or adapter rule: {'original_value': 'A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of Olorinab in Subjects With Irritable Bowel Syndrome Experiencing Abdominal Pain', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-10-31T23:27:35.187692+00:00
Published At: 2022-10-12T00:00:00+00:00
Record Updated At: 2025-01-30
Results Posted At: 2022-10-12
Source Retrieved At: 2026-10-31T22:18:52.668840+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

protocolSection.conditionsModule.conditions: ["Irritable Bowel Syndrome"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2025-01-30", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT04043455"
protocolSection.identificationModule.officialTitle: "A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of Olorinab in Subjects With Irritable Bowel Syndrome Experiencing Abdominal Pain"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct: {"date": "2022-10-12", "type": "ACTUAL"}

{'armGroupLabels': ['Olorinab low dose (Main Study)'], 'description': 'Olorinab Dose 1 capsule or tablet by mouth, 3 times per day up to 12 weeks', 'name': 'Olorinab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Olorinab medium dose (Main Study)'], 'description': 'Olorinab Dose 2 capsule or tablet by mouth, 3 times per day up to 12 weeks', 'name': 'Olorinab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Olorinab high dose (Main Study)'], 'description': 'Olorinab Dose 3 capsule or tablet by mouth, 3 times per day up to 12 weeks', 'name': 'Olorinab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Placebo (Main Study)'], 'description': 'Olorinab matching placebo capsule or tablet by mouth, 3 times per day up to 12 weeks', 'name': 'Placebo', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Olorinab (Long-Term Extension)'], 'description': 'Olorinab Dose 2 capsule or tablet by mouth, 3 times per day up to 52 weeks', 'name': 'Olorinab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Olorinab (Long-Term Extension)'], 'description': 'Olorinab Dose 3 capsule or tablet by mouth, 3 times per day up to 52 weeks', 'name': 'Olorinab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.